25.7 C
New York
Thursday, June 4, 2026

Tag: Everest Medicines

newssourceFORcompanyinformationcontent1marketreleases

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to...

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and...

Everest Medicines Announces Full Approval of NEFECON® in Taiwan

SHANGHAI, Aug. 6, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Everest Medicines Announces Share Placement to Raise Approximately HK$1,572.50 Million

SHANGHAI, July 25, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest" or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and...

Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai

SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative...

Everest Medicines Announces Updated Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of...

As of March 21st, 2025, longer follow-up data was collected from the ongoing Ph1b/2a study of EVER001: in Cohort 1, 11 patients completed 52...

Everest Medicines to Host Virtual Nephrology-Focused KOL Event on June 30, 2025

SHANGHAI, June 26, 2025 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it will host a virtual nephrology-focused key opinion leader (KOL) event on Monday, June 30, 2025 at 8:00 AM ET. For English speakers, please click here to register. For individuals preferring instant Chinese translation, please click here.

Everest Medicines Announces Official Publication of the Specifications for Antimicrobial Susceptibility Testing of Eravacycline (2025)

SHANGHAI, June 23, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing,...

Everest Medicines Presents Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of Novel BTK Inhibitor EVER001 at the 62nd Congress of the...

EVER001 is a covalent reversible BTK inhibitor with potentially best-in-class characteristics for the treatment of primary membranous nephropathy (pMN) and other autoimmune renal diseases, including...

NEFECON®: New Results at ERA 2025 Demonstrate Treatment Benefit of the ‘Treat Early’ Strategy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust support for the new disease...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsEverest Medicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers